1,260 reports of this reaction
3.4% of all PHENYTOIN reports
#5 most reported adverse reaction
CONVULSION is the #5 most commonly reported adverse reaction for PHENYTOIN, manufactured by Viatris Specialty LLC. There are 1,260 FDA adverse event reports linking PHENYTOIN to CONVULSION. This represents approximately 3.4% of all 36,996 adverse event reports for this drug.
Patients taking PHENYTOIN who experience convulsion should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONVULSION is moderately reported among PHENYTOIN users, representing a notable but not dominant share of adverse events.
In addition to convulsion, the following adverse reactions have been reported for PHENYTOIN:
The following drugs have also been linked to convulsion in FDA adverse event reports:
CONVULSION has been reported as an adverse event in 1,260 FDA reports for PHENYTOIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONVULSION accounts for approximately 3.4% of all adverse event reports for PHENYTOIN, making it a notable side effect.
If you experience convulsion while taking PHENYTOIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.